County Galway-based Chanelle Pharma group reported pretax profits increasing 51.5 per cent to €16.75 million in the 14-month period to end-April 2025 as revenues rose 17 per cent from €190 million to €223.19 million, according to an Irish Times report.

Chanelle Pharma is Ireland's largest manufacturer of generic pharmaceuticals for human and animal health. In February 2024, founder Michael Burke sold the company he established over 40 years ago to British private equity group Exponent for €183.9 million.

From its Loughrea base, the group employs more than 700 people across Ireland, Britain, Portugal and Jordan, exporting to over 90 countries. A breakdown of revenues shows €114.46 million was generated in the Republic, €94.7 million in Europe and €14 million in rest of world markets.

"Trading since the start of the new financial year has been encouraging," directors stated in accounts filed with Companies House. "The outlook remains positive with strong market demand for our products and delivery pipeline. We believe in the capability of our people and our ability to execute our strategy and therefore remain confident in our future growth prospects."

Numbers employed totalled 685, comprising 416 in operations and 269 in administration. Staff costs reached €44 million. Pay to directors amounted to €618,263 including pension contributions of €16,068. The highest-paid director received €461,831 during the year.

The group maintains a structured development programme aimed at identifying and bringing new pharmaceutical products to market. Directors described investment in development as key to strengthening the group's competitive position in pharmaceutical manufacturing.

Access the complete article on Chanelle Pharma's financial performance and European manufacturing operations.